~~<i id='647A255583'><strike id='647A255583'><tt id='647A255583'><pre id='647A255583'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：focus 2025-09-30 17:43:40 - browse：17664

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Parkland mass shooting to be reenacted for lawsuit

knowledge

hotspot

explore

leisure time

focus

knowledge

0:49The"1200building"atMarjoryStonemanDouglasHighSchool,thecrimescenewherethe2018shootingstookplace,

WSS

Slain Parkland victim's father speaks out following reenactment

Special counsel alerts court to Trump’s social media post

Pediatricians' group reaffirms support for gender

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Medical mystery: When an infection after surgery isn’t what it seems

Wikipedia

fashion

knowledge

Psychedelics group wrestles with new pharma identity

Calls for Trump's election interference trial to be televised part of long debate

ChatGPT in medicine: STAT answers readers' burning questions

White House drug czar issues call for 'recovery

In age of alternative facts, a scholarly course on calling out crap

What health policies could hitch a ride on a spending bill?

Apple is now the first public company to be valued at $3 trillion

Today's health inequities arise from racist U.S. history, say experts

BioMarin wins approval for gene therapy to treat hemophilia A

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

hotspot

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Medical mystery: When an infection after surgery isn’t what it seems

After decades in use, heart stents finally beat placebo

Medical schools are missing the mark on artificial intelligence

New company forms to vet health AI models, root out weaknesses

explore

leisure time

focus

knowledge